Searchable abstracts of presentations at key conferences in endocrinology

ea0068p8 | Abstracts | UKINETS2019

Audit of the appropriateness and outcomes of 24-hour urinary 5-HIAA testing in a UK general hospital

Higginson Kieren , Pritchard D Mark

Introduction: Some functional neuroendocrine tumours (NETs) secrete serotonin, leading to the symptoms of carcinoid syndrome (e.g. diarrhoea and flushing). In this condition, increased urinary concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) are often detected. Measurement of 24-hour urinary 5-HIAA is therefore used to investigate patients with confirmed or suspected carcinoid syndrome. We sought to evaluate the appropriateness and effectiveness o...

ea0068p18 | Abstracts | UKINETS2019

Frequency and causes of elevated fasting plasma concentrations of a panel of gut hormones in routine clinical practice

Butler Olivia , Mekhael Monica , Ahmed Arslan , Pritchard D Mark

Introduction: In the UK, the fasting plasma concentrations of a panel of gut hormones (vasoactive intestinal peptide (VIP), gastrin, pancreatic polypeptide, glucagon and somatostatin as well as chromogranin A) are frequently measured during the evaluation of patients who have confirmed or clinically suspected neuroendocrine tumours (NETs). However, elevated concentrations of these hormones are sometimes also detected in patients who have no other evidence of a NET. We sought t...

ea0060p08 | (1) | UKINETS2018

Periodic endoscopic surveillance in patients with low risk type I gastric neuroendocrine tumours (gNETs) also detects associated gastric adenocarcinoma in a subset of patients

Hu Haiyi , Exarchou Klaire , Moore Andrew , Pritchard D Mark

Background: People who have autoimmune atrophic gastritis commonly develop type 1 gNETs, but are also at increased risk of developing gastric adenocarcinoma. Type I gNET patients usually have multiple gastric polyps and have an excellent prognosis when the polyps measure.Method: Retrospective audit of type I gNET patients managed within Liverpool ENETS Centre of Excellence 2004–2018.Results: 86 patients (median age 67 years, 5...

ea0046p2 | (1) | UKINETS2016

68Gallium-DOTANOC (68Ga-DOTANOC) positron emission tomography (PET) imaging in Bronchial Carcinoids (BC): multicentre evaluation of its role in clinical practice

Lamarca Angela , Pritchard D. Mark , Westwood Thomas , Papaxoinis George , Vinjamuri Sobhan , Valle Juan W , Manoharan Prakash , Mansoor Wasat

Background: New nuclear medicine imaging techniques have improved diagnosis, staging and treatment planning for BC. 68Ga-DOTA PET is preferable to standard somatostatin receptor scintigraphy where available (ENETS guidelines); however, its role in the management of BC remains unclear.Methods: All consecutive patients diagnosed with BC from two ENETS Centres of Excellence were identified retrospectively; patients with high grade tumours or lack...

ea0060p18 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with sporadic pancreatic neuroendocrine tumours (pNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanais Michail , Jaffa Matthew , Lamarca Angela , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , O'Reilly Derek , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Pritchard D Mark , Hubner Richard , Srirajaskanthan Raj , Ramage John , Raraty Mike , Ganeh Paula , Fenwick Steve , Valle Juan , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) are rare tumours (prevalence 4/100,000). Diagnosis and staging of panNETs requires biochemical screening, cross-sectional imaging (with CT/MRI), endoscopic ultrasound (EUS) and where available, functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT due to its reported higher sensitivity and specificity.Methods: A retrospective, electronic case note study was ca...